These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29593436)

  • 21. Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis.
    Cardenas-Blanco A; Machts J; Acosta-Cabronero J; Kaufmann J; Abdulla S; Kollewe K; Petri S; Schreiber S; Heinze HJ; Dengler R; Vielhaber S; Nestor PJ
    Neuroimage Clin; 2016; 11():408-414. PubMed ID: 27104135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.
    Watanabe H; Atsuta N; Nakamura R; Hirakawa A; Watanabe H; Ito M; Senda J; Katsuno M; Izumi Y; Morita M; Tomiyama H; Taniguchi A; Aiba I; Abe K; Mizoguchi K; Oda M; Kano O; Okamoto K; Kuwabara S; Hasegawa K; Imai T; Aoki M; Tsuji S; Nakano I; Kaji R; Sobue G
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):230-6. PubMed ID: 25548957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials.
    van Eijk RPA; de Jongh AD; Nikolakopoulos S; McDermott CJ; Eijkemans MJC; Roes KCB; van den Berg LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 May; 22(3-4):300-307. PubMed ID: 33527843
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis.
    Ackrivo J; Hansen-Flaschen J; Wileyto EP; Schwab RJ; Elman L; Kawut SM
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30728207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD005225. PubMed ID: 23235621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials.
    Rutkove SB; Zhang H; Schoenfeld DA; Raynor EM; Shefner JM; Cudkowicz ME; Chin AB; Aaron R; Shiffman CA
    Clin Neurophysiol; 2007 Nov; 118(11):2413-8. PubMed ID: 17897874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open-Access ALS Clinic Trials database.
    Bald EM; Nance CS; Schultz JL
    Muscle Nerve; 2021 Apr; 63(4):572-576. PubMed ID: 33428242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variation in noninvasive ventilation use in amyotrophic lateral sclerosis.
    Thakore NJ; Lapin BR; Pioro EP; Aboussouan LS
    Neurology; 2019 Jul; 93(3):e306-e316. PubMed ID: 31182506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
    Rudnicki SA; Berry JD; Ingersoll E; Archibald D; Cudkowicz ME; Kerr DA; Dong Y
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Jan; 14(1):44-51. PubMed ID: 22985432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multipoint incremental motor unit number estimation versus amyotrophic lateral sclerosis functional rating scale and the medical research council sum score as an outcome measure in amyotrophic lateral sclerosis.
    Jagtap SA; Kuruvilla A; Govind P; Nair MD; Sarada C; Varma RP
    Ann Indian Acad Neurol; 2014 Jul; 17(3):336-9. PubMed ID: 25221407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does including machine learning predictions in ALS clinical trial analysis improve statistical power?
    Zhou N; Manser P
    Ann Clin Transl Neurol; 2020 Oct; 7(10):1756-1765. PubMed ID: 32862509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).
    Smith RA; Macklin EA; Myers KJ; Pattee GL; Goslin KL; Meekins GD; Green JR; Shefner JM; Pioro EP
    Eur J Neurol; 2018 Jul; 25(7):907-e66. PubMed ID: 29577526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.
    Karanevich AG; Statland JM; Gajewski BJ; He J
    BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial.
    Chen PC; Hsieh YC; Huang CC; Hu CJ
    Medicine (Baltimore); 2020 May; 99(22):e20423. PubMed ID: 32481440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS.
    Goutman SA; Brown MB; Glass JD; Boulis NM; Johe K; Hazel T; Cudkowicz M; Atassi N; Borges L; Patil PG; Sakowski SA; Feldman EL
    Ann Clin Transl Neurol; 2018 Jun; 5(6):730-740. PubMed ID: 29928656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.